289 related articles for article (PubMed ID: 15365603)
1. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction.
Koch RO; Graziadei IW; Schulz F; Nachbaur K; Königsrainer A; Margreiter R; Vogel W
Transpl Int; 2004 Oct; 17(9):518-24. PubMed ID: 15365603
[TBL] [Abstract][Full Text] [Related]
2. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.
Schlitt HJ; Barkmann A; Böker KH; Schmidt HH; Emmanouilidis N; Rosenau J; Bahr MJ; Tusch G; Manns MP; Nashan B; Klempnauer J
Lancet; 2001 Feb; 357(9256):587-91. PubMed ID: 11558484
[TBL] [Abstract][Full Text] [Related]
3. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction.
Ponton C; Vizcaíno L; Tomé S; Otero E; Molina E; Castroagudín JF; López-Lago A; Varo Pérez E
Transplant Proc; 2010 Mar; 42(2):656-9. PubMed ID: 20304216
[TBL] [Abstract][Full Text] [Related]
4. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
[TBL] [Abstract][Full Text] [Related]
5. Introduction of mycophenolate mofetil in maintenance liver transplant recipients: what can we expect? Results of a 10-year experience.
Dumortier J; Guillaud O; Pittau G; Salandre J; Adham M; Scoazec JY; Boillot O
Transplant Proc; 2010 Sep; 42(7):2602-6. PubMed ID: 20832553
[TBL] [Abstract][Full Text] [Related]
6. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
7. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
[TBL] [Abstract][Full Text] [Related]
8. Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction.
Kornberg A; Küpper B; Thrum K; Krause B; Büchler P; Kornberg J; Sappler A; Altendorf-Hofmann A; Wilberg J; Friess H
Dig Dis Sci; 2011 Jan; 56(1):244-51. PubMed ID: 20824504
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation.
Moreno JM; Rubio E; Gómez A; Lopez-Monclus J; Herreros A; Revilla J; Navarrete E; Sánchez Turrión V; Jimenez M; Cuervas-Mons V
Transplant Proc; 2003 Aug; 35(5):1874-6. PubMed ID: 12962831
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
[TBL] [Abstract][Full Text] [Related]
12. Renal recovery after conversion to an everolimus-based immunosuppression in early and late heart transplant recipients: a 12-month analysis.
Michel S; Bigdeli AK; Hagl C; Meiser B; Kaczmarek I
Exp Clin Transplant; 2013 Oct; 11(5):429-34. PubMed ID: 24128136
[TBL] [Abstract][Full Text] [Related]
13. [Mycophenolate mofetil-based calcineurin inhibitor reduced immunosuppressive protocol for the improvement of renal dysfunction after liver transplantation].
Lai W; Lu SC; Wang ML; Zhang J; Wu JS; Dai J; Zeng DB; Xia RP; Li N
Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1529-32. PubMed ID: 19953878
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation.
Créput C; Blandin F; Deroure B; Roche B; Saliba F; Charpentier B; Samuel D; Durrbach A
Liver Transpl; 2007 Jul; 13(7):1004-10. PubMed ID: 17600361
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
Barrera Pulido L; Alamo Martínez JM; Pareja Ciuró F; Gómez Bravo MA; Serrano Díez-Canedo J; Bernal Bellido C; Suárez Artacho G; García González I; Pascasio Acevedo JM; Bernardos Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2985-7. PubMed ID: 19010168
[TBL] [Abstract][Full Text] [Related]
17. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant.
Biselli M; Vitale G; Gramenzi A; Riili A; Berardi S; Cammà C; Scuteri A; Morelli MC; Grazi GL; Pinna AD; Andreone P; Bernardi M
Clin Transplant; 2009; 23(2):191-8. PubMed ID: 19210525
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil in liver transplant patients with calcineurin-inhibitor-induced renal impairment.
Ko HH; Greanya E; Lee TK; Steinbrecher UP; Erb SR; Yoshida EM
Ann Hepatol; 2008; 7(4):376-80. PubMed ID: 19034239
[TBL] [Abstract][Full Text] [Related]
19. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
Raimondo ML; Dagher L; Papatheodoridis GV; Rolando N; Patch DW; Davidson BR; Rolles K; Burroughs AK
Transplantation; 2003 Jan; 75(2):186-90. PubMed ID: 12548120
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
